Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 25, 2024
Product Development
Innate immune activators among first-in-human debuts at AACR
Spotlight on early-stage solid tumor trials with emerging innate immune targets: ALPK1 and ENPP1
BioCentury | Apr 9, 2024
Discovery & Translation
AACR brings new modalities, new targets to glioblastoma
BioCentury identifies new CAR T cell designs, ADCs and other modalities, plus 37 preclinical targets for
BioCentury | Jul 7, 2023
Discovery & Translation
Smaller gene editors, Resilience’s cell-free antibody discovery platform and more
BioCentury’s roundup of translational innovations
BioCentury | Mar 16, 2022
Finance
Taking ‘patient’ approach, Frazier preparing to write bigger checks from new $987M fund
Continuing previous strategy, Frazier to invest across spectrum from company creation to publicly traded biotechs
BioCentury | Jul 24, 2020
Finance
Four more biotech IPOs reach the market, but no big first-day pop in the bunch
BioCentury | Jul 3, 2020
Finance
On heels of $100M raise, Annexon joins burgeoning IPO queue
Asian biopharma IPOs headline week that had three U.S. companies enter NASDAQ IPO queue
BioCentury | Jan 16, 2020
Financial News
Frazier taking new company creation angle with $617M fund
Armed with $617M in its Fund X, Frazier to dip its toes in early-stage company creation
BioCentury | Jul 15, 2019
Company News
Via Mavupharma takeout, AbbVie gets first-in-class STING target
BioCentury | Jan 26, 2018
Emerging Company Profile
Quenching calcium
How Inozyme’s ERT could treat a broad range of calcification disorders
Items per page:
1 - 10 of 16